These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29961279)

  • 1. [Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia].
    Xue W; Yang JJ; Zhao J; Ren T; Feng FZ; Wan XR; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):377-383. PubMed ID: 29961279
    [No Abstract]   [Full Text] [Related]  

  • 2. Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5.
    Li Y; Kong Y; Wan X; Feng F; Ren T; Zhao J; Yang J; Xiang Y
    Oncologist; 2021 Dec; 26(12):e2209-e2216. PubMed ID: 34396643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
    Yang J; Xiang Y; Wan X; Feng F; Ren T
    Gynecol Oncol; 2016 Oct; 143(1):68-72. PubMed ID: 27426306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
    Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
    Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
    Mao Y; Wan X; Lv W; Xie X
    Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
    Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
    [No Abstract]   [Full Text] [Related]  

  • 7. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
    Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
    J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
    Deng L; Zhang J; Wu T; Lawrie TA
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia.
    Ji M; Jiang S; Zhao J; Wan X; Feng F; Ren T; Yang J; Xiang Y
    Br J Cancer; 2022 Aug; 127(3):524-530. PubMed ID: 35459802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis.
    Li J; Yue H; Wang X; Chen R; Lu X
    Eur J Obstet Gynecol Reprod Biol; 2019 Jul; 238():164-169. PubMed ID: 31136884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
    Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
    Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy regimen with floxuridine, dactinomycin, etoposide, and vincristine as primary treatment for gestational trophoblastic neoplasia.
    Wang T; Feng FZ; Xiang Y; Wan XR; Ren T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Jun; 36(3):300-4. PubMed ID: 24997824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
    Feng F; Xiang Y; Wan X; Geng S; Wang T
    Ann Oncol; 2011 Jul; 22(7):1588-1594. PubMed ID: 21239399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
    Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
    Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
    Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
    Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
    Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
    Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
    Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X
    Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.